curriculum vitae lance richard mcmahon, phd …neuropharmacology 2016 dec;116:9-17. 4. cunningham...

DateofPreparation:05/11/2011

1

CURRICULUMVITAELanceRichardMcMahon,PhD

CONTACTINFORMATION

MailingAddress: DepartmentofPharmacodynamics CollegeofPharmacy UniversityofFlorida

1345CenterDrive JHMHSCP1-20B

POBox100487Gainesville,FL32610

Office: (352)273-7851 Fax: (352)273-7705 Email: [email protected]

EDUCATION Year Degree Discipline Institution/Location 1997 PhD BehavioralandCellular TexasA&MUniversity,CollegeStation,TX Neuroscience

1994 MS BehavioralandCellular TexasA&MUniversity,CollegeStation,TX Neuroscience

1992 BA Psychology UniversityofPennsylvania,Philadelphia,PA Penn psychology department is the oldest continuously functioning psychology

departmentinNorthAmerica;asanundergraduatemajorIwasprivilegedtobetaughtbysomeoftheworld’spremierpsychologyscholarsincludingDrs.MartinSeligman,RobertRescorla,RobertSeyfarth,DorothyCheney,SaulSternberg,PaulRosin,andLilaGleitman

TRAINING

Postdoctoral training in the laboratory of Kathryn Cunningham, PhD, Chauncey Leake DistinguishedProfessorofPharmacologyandViceChairman

Years Department Institution/Location

01/1998-05/2000 Pharmacology UniversityofTexasMedicalBranch

andToxicology Galveston,TX


2

ACADEMICAPPOINTMENTS

Years AcademicRank Department/Institution/Location08/2017-present ProfessorandChair DepartmentofPharmacodynamics Tenured UniversityofFlorida09/2012-08/2017 AssociateProfessor DepartmentofPharmacology

Tenured UniversityofTexasHealthSanAntonio

01/2006-08/2012 AssistantProfessor DepartmentofPharmacologyTenuretrack UniversityofTexasHealthSanAntonio

09/2002-12/2005 AssistantProfessor DepartmentofPharmacology

Researchtrack UniversityofTexasHealthSanAntonio06/2000-08/2002 Instructor DepartmentofPharmacology

Researchtrack UniversityofTexasHealthSanAntonio

08/1997-05/2000 AdjunctProfessor DepartmentofPsychologyUniversityofHoustonofClearLakeClearLake,TX

RESEARCHADMINISTRATIVEEXPERIENCE

Council of Principle Investigators, UT Health San Antonio, electedmember 2014-present, workedside-by-sidewith theUniversity President, Vice President for Research, Human Resources, Office ofSponsoredPrograms,InstitutionalAnimalCareProgram,HumanResearchProtectionOffice,andDeansof Medicine, Dentistry, Nursing, and Allied Health to remove research impediments; streamlinedIACUC/IRB/EHS protocol submission, approval, and amendment processes, hiring processes, andtechnologytransfer,commercializationprocedures

Director,CannabinoidandNicotineNeurobiologyLaboratory,UTHealthSanAntonio,2007-present,directed postdoctoral trainees, predoctoral trainees, and research technicians in an internationallyrecognized research operation resulting in close to $10 million in external funding, over 40publications, invited presentations both domestically and internationally, and research honors andawards;coordinatedresearchoperationsdaily,365daysperyear;createdSOPsandGLPforrunningabehavioralpharmacologyresearchlaboratoryin40rhesusmonkeys;maintainedfederalandstateDEAlicenses;DEAliaisonforinspections;directedlaboratorysecuritywiththeUniversityPoliceDepartmentperDEApolicy;developedtrackingandmonitoringsystemsforuseandstorageofSchedule1-5drugs;set policies for TB testing of staff and non-human primates; set guidelines for human emergencyresponse to rhesusmonkey tissueexposure;managedUSDA site inspectionsof non-humanprimateresearchfacilities


3

PrincipalInvestigator,$9millionresearchprogramcontinuouslyfundedbyNIH2003-2019,inchargeof employing scores of research staffwith aminimumbachelor’s degree (required); responsible forinterviewing,hiring,annualperformancereviews,professionaldevelopment,remediation,promotions,and grievances/termination; upon leaving my lab, my employees have entered or graduated fromdoctoralresearchprograms,medicalschools,dentalschools,andnursingschools

Investigator, $6 million NIH cost-sharing animals housing and laboratory renovation 2006-2007,designed state-of-the-artwet lab facilities, behavioral testing rooms, and animal housing rooms fornon-humanprimates,pigeons,and rodents; resolvedarchitecturaldesign issuesand supervisedcostoverruns; coordinated faculty, facilities management, and contractors to minimize disruption toongoingresearchoperations

FreedomofInformationAct,UTHealthSanAntonioLiaison,workedwithlawyerstohelpshapetheUniversity’sresponsetorequestsforinformationregardinguseofliveanimalsinresearchasrequiredbylaw

IACUC,UTHealthSanAntonio,member2007-2010

TECHNOLOGYTRANSFERANDCOMMERCIALIZATION

EntrepreneurialFacultyScholars,UTHealthSanAntonio,member2017

TopicsinTranslationalMedicalProductDevelopmentWorkshops,UTHealthSanAntonioOfficeoftheVPR2017

LessonslearnedasanFDAreviewer,AllisonKomiyama,PhD,AcknowledgeRegulatoryStrategies

Match your product to agency mission for SBIR/STTR success, Michael Kurek, PhD, BBCEntrepreneurialTrainingandConsultingLLC

Marketingandfinancingyourtechnology,MarkStandeford,CEO,Cardiovate

Corporate partnering and strategic alliances, IsaacRodriguez-Chavez, PhD, andBeckyCap,MBA,COO,GenCure(subsidiaryofBioBridgeGlobal)

Reimbursement strategy and health economics, Shabnam Vaezzadeh, MD, Former VP of GlobalMedicalAffairsforKCI

Bestpracticesforgrowingalifesciencesecosystem,JaniceBourque,formerPresidentofMassBio,currentManagerwithHerculesCapitalinBoston,MA

INVENTIONDISCLOSURES,PATENTAPPLICATIONS,LEADINVENTOR

USProvisionalPatentApplication62/501,536(filed4May2017)MethodsofTreatingSyntheticCannabinoidToxicityorOverdosewithRimonabant


4

InventionId:IP-17/0090,PatentapplicationpendingTitle:Sustainedreleasemecamylamineforsmokingcessation

LICENSES

DrugEnforcementAgencySchedule1Registration#RM0350203DrugEnforcementAgencySchedules2-5Registration#0349729TexasDepartmentofPublicSafetySchedule1Registration#30122156TexasDepartmentofPublicSafetySchedules2-5Registration#B0153229

ACADEMICAFFAIRSADMINISTRATIVETRAINING

IDEAWorkshop,KansasCity,September9,2016,Topics:CreatingaBalancedFacultyEvaluation,UsingDatatoInformFacultyDevelopmentProgramming,UsingStudentRatingsDataforOutcomesAssessment


5

RESEARCH

ResearchGrants

Currentlyactive

Project#:R01DA025267FundingAgency:NIH/NationalInstituteonDrugAbuseTitle:Nicotinedependence:neuropharmacologyinmonkeysPeriod:04/2014-01/2019Role:PrincipalInvestigatorTotalCosts:$1,801,138Grant Detail: The aim of this grant is to use drug discrimination and othermeasures of withdrawal tocharacterize the neuropharmacology of nicotine dependence and to examine relationships betweennicotinic receptor subtypes, nicotinic agonist efficacy, and behavioral effects of currently existingpharmacotherapiesfortobaccodependence.Project#:T32DA031115FundingAgency:NIH/NationalInstituteonDrugAbuseTitle:Trainingindrugabuseresearch:behaviorandneurobiologyPeriod:07/2011-06/2021Role:TrainingFacultyProject#:T32NS082145FundingAgency:NIH/NationalInstituteofNeurologicalDisordersandStrokeTitle:Integratedgraduatetraininginneuroscience,UTHSCSAPeriod:07/2013-06/2018Role:TrainingFaculty

CompletedProject#:R01DA025267FundingAgency:NIH/NationalInstituteonDrugAbuseTitle:Researchsupplementstopromotediversityinhealth-relatedresearch,FernandoMouraPeriod:04/2014-01/2019Role:PrincipalInvestigatorCosts:$42,000/yearProject#:R01DA019222FundingAgency:NIH/NationalInstituteonDrugAbuseTitle:TreatmentofcannabinoidwithdrawalinRhesusmonkeysPeriod:07/2009-06/2016Role:PrincipalInvestigatorTotalCosts:$1,794,061


6

Project#:R01DA025267FundingAgency:NIH/NationalInstituteonDrugAbuseTitle:Nicotinedependence:neuropharmacologyinmonkeysPeriod:04/2009-01/2014Role:PrincipalInvestigatorTotalCosts:$1,614,189Project#:R01DA026781FundingAgency:NIH/NationalInstituteonDrugAbuseTitle:Pharmacotherapyofcannabinoidwithdrawal:pre-clinicalstudiesPeriod:07/2009-06/2012Role:PrincipalInvestigatorTotalCosts:$718,083Project#:R01DA19222FundingAgency:NIH/NIDATitle:TreatmentofcannabinoidwithdrawalinrhesusmonkeysPeriod:09/2004-09/2009Role:PrincipalInvestigator TotalCosts:$1,774,913Project#:R21DA15468FundingAgency:NIH/NIDATitle:DrugDiscriminationandTHCwithdrawalinmonkeysPeriod:09/2003-09/2006Role:PrincipalInvestigatorTotalCosts:$438,000FundingAgency:UTHealthSanAntonio-CompetitiveResearchEnhancementFundTitle:EffectsofSR141716AincannabinoidtreatedmonkeysPeriod:01/2001-12/2001Role:PrincipalInvestigatorTotalCosts:$50,000Project#:F32DA05879FundingAgency:NIH/NationalInstituteonDrugAbuseTitle:Cocainebehaviors:Roleofserotonin5-HT4and5-HT6receptorsPeriod:09/1998-05/2000Role:PrincipalInvestigatorTotalCosts:$51,100


7

ResearchProfile Myresearch laboratoryusesbehavioralapproachestoexaminepharmacologicmechanismsunderlyingdrugabuseanddependence.Wearecurrentlystudyingcannabinoids(i.e.cannabisandsyntheticcannabinoids)andnicotine(i.e.tobacco)andpreviousworkhasfocusedoncocaineandotherdopamineagonists,GABA-relatedsedative hypnotics, and opioid analgesics. Studies supported by one ongoing NIH grant (Treatment ofcannabinoid withdrawal in rhesus monkeys) have demonstrated that the intrinsic activity or efficacy ofcannabinoid agonists determines themagnitude of tolerance resulting from chronic treatment. Under thisgrant, novel procedures in rhesus monkeys have been developed to measure the subjective effects ofwithdrawalfromTHC,thechemicalresponsiblefortheabuseanddependenceliabilityofcannabis.Wehaveusedthesenovelprocedurestodemonstratethatsomecannabinoidandalpha-adrenergicagonistseffectivelyattenuate THC withdrawal. Furthermore, these studies have suggested that the enzymes responsible fordegrading the endogenous cannabinoid neurotransmitters are down-regulated in cannabinoid tolerant anddependentmonkeys.StudiesunderasecondongoingNIHgrant(Nicotinedependence:neuropharmacologyinmonkeys)have revealed conditionsunderwhichnicotinediffers fromother smoking cessationaids suchasvarenicline.Vareniclinewasshowntomimictheeffectsofnicotine,butwasmuchlesscapableofdoingsoinnicotine-dependent monkeys. We are using these procedures to better understand the nicotinic receptormechanismsthatdifferentiatetheclinicaleffectivenessofcurrentlyavailablesmokingcessationproductsandnovelexperimentaldrugstoimprovetreatmentoftobaccodependence.PublishedPeer-ReviewedJournalArticles(81total)

1. HrubaL,McMahonLR.Apparentaffinityestimatesandreversalof theeffectsofsyntheticcannabinoidsAM-2201, CP-47,497, JWH-122, and JWH-250 by rimonabant in rhesusmonkeys. J Pharmacol Exp Ther2017Aug;362(2):278-286.

2. DeMouraFB,McMahonLR.Thecontributionofα4β2andnon-α4β2nicotinicacetylcholinereceptorstothe discriminative stimulus effects of nicotine and varenicline inmice. Psychopharmacology (Berl) 2017Mar;234(5):781-792.

3. Moerke MJ, Zhu AZ, Tyndale RF, Javors MA,McMahon LR. The discriminative stimulus effects of i.v.nicotine in rhesus monkeys: Pharmacokinetics and apparent pA2 analysis with dihydro-β-erythroidine.Neuropharmacology2016Dec;116:9-17.

4. Cunningham CS, Moerke MJ, Javors MA, Carroll FI,McMahon LR. Attenuated nicotine-like effects ofvarenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily. Br JPharmacol2016Dec;173:3454-3466.

5. McMahonLR. Enhanceddiscriminative stimuluseffectsofΔ9-THC in thepresenceof cannabidioland8-OH-DPATinrhesusmonkeys.DrugAlcoholDepend2016Aug;165:87-93.

6. MoerkeMJ,deMouraFB,KoekW,McMahonLR.Effectsofnicotineincombinationwithdrugsdescribedas positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus andhypothermiceffectsinmice.EurJPharmacol2016May;786:169-178.


8

7. De Moura FB,McMahon LR. Differential Antagonism and Tolerance/Cross-Tolerance Among Nicotinic

Acetylcholine Receptor Agonists: Scheduled-Controlled Responding and Hypothermia in C57BL/6JMice.BehavPharmacol2016Apr;27(2-3SpecIssue):240-248.

8. McMahonLR.Therise(andfall?)ofdrugdiscriminationresearch.DrugAlcoholDepend2015Jun;151:284-288.

Invited review: This review examines the history and current application of drug discrimination inbiomedicalresearchanddiscussestrendsinitsuseovertheyears.

9. GhoshS,KinseySG,LiuQ,HrubaL,McMahonLR,WiseLE,AbdullaRA,SelleyDE,Sim-SelleyL,CravattBF,

LichtmanAH. Full FAAH inhibition combinedwithpartialmonoacylglycerol lipase inhibition:Augmentedandsustainedantinociceptiveeffectswithnegligiblecannabimimeticsideeffectsinmice.JPharmacolExpTher2015Aug;354(2):111-120.

10. HrubaL,SeillierA,ZakiA,CravattBF,LichtmanAH,GiuffridaA,McMahonLR.Simultaneousinhibitionof

fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) shares discriminative stimuluseffectswith∆9-THCinmice.JPharmacolExpTher2015May;353(2):261-268.

11. Cunningham CS, Moerke MJ, McMahon LR. The discriminative stimulus effects of mecamylamine in

nicotine-treatedanduntreatedrhesusmonkeys.BehavPharmacol2014Aug;25(4):296-305.12. Rodriguez JS, McMahon LR. JWH-018 in rhesus monkeys: differential antagonism of discriminative

stimulus,rate-decreasing,andhypothermiceffects.EurJPharmacol2014Oct5;740:151-159.13. RodriguezJS,CunninghamCS,MouraFB,OndachiP,CarrollFI,McMahonLR.Discriminativestimulusand

hypothermiceffectsof somederivativesof thenAChRagonistepibatidine inmice.Psychopharmacology(Berl)2014Dec;231(23):4455-4466.

14. Ginsburg BC, Hruba L, Zaki A, Javors MA, McMahon LR. Blood levels do not predict behavioral or

physiological effects ofΔ⁹-tetrahydrocannabinol in rhesusmonkeyswithdifferent patternsof exposure.DrugAlcoholDepend2014Jun1;139:1-8.

15. Hruba L, McMahon LR. The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus

effectsinrhesusmonkeys.EurJPharmacol2014Mar15;727:35-42.16. CunninghamCS,McMahonLR.Multiplenicotine trainingdoses inmiceasabasis fordifferentiating the

effectsofsmokingcessationaids.Psychopharmacology(Berl)2013Jul;228(2):321-333.17. HrubaL,GinsburgBC,McMahonLR.Apparentinverserelationshipbetweencannabinoidagonistefficacy

and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys. JPharmacolExpTher2012Sep;342(3):843-849.


9

18. GouldGG,SeillierA,WeissG,GiuffridaA,BurkeTF,HenslerJG,RockC,TristanA,McMahonLR,SalazarA,O'Connor JC,SatsangiN,SatsangiRK,GuTT,TreatK, SmolikC, SchultzST.Acetaminophendifferentiallyenhancessocialbehaviorandcorticalcannabinoidlevelsininbredmice.ProgNeuropsychopharmacolBiolPsychiatry2012Aug7;38(2):260-269.

19. Cunningham CS, Javors MA,McMahon LR. Pharmacologic characterization of a nicotine-discriminative

stimulusinrhesusmonkeys.JPharmacolExpTher2012Jun;341(3):840-849.20. Schulze DR, Carroll FI, McMahon LR. Interactions between dopamine transporter and cannabinoid

receptor ligands in rhesus monkeys. Psychopharmacology (Berl) 2012 Aug;222(3):425-438.

21. Ginsburg BC, McMahon LR, Sanchez JJ, Javors MA. Purity of synthetic cannabinoids sold online forrecreationaluse.JAnalToxicol2012Jan;36(1):66-68.

22. Ginsburg BC, Schulze DR, Hruba L,McMahon LR. JWH-018 and JWH-073: Δ9-tetrahydrocannabinol-like

discriminativestimuluseffectsinmonkeys.JPharmacolExpTher2012Jan;340(1):37-45.23. StewartJL,McMahonLR.ThefattyacidamidehydrolaseinhibitorURB597:interactionswithanandamide

inrhesusmonkeysBrJPharmacol2011;Sep;164(2b):655-666.24. Singh H, Schulze D,McMahon LR. Tolerance and cross-tolerance to cannabinoids in mice: schedule-

controlledrespondingandhypothermiaPsychopharmacology(Berl)2011Jun;215(4):665-675.

25. Cunningham CS,McMahon LR. The effects of nicotine, varenicline, and cytisine on schedule-controlledresponding in mice: differences in [alpha]4[beta]2 nicotinic receptor activation Eur J Pharmacol2011;654(1):47-52.

26. McMahonLR. ChronicΔ9-tetrahydrocannabinol treatment in rhesusmonkeys:differential toleranceand

cross-toleranceamongcannabinoidsBrJPharmacol2011Mar;162(5):1060-1073.27. JavorsMA,SanchezJJ,McMahonLR.Quantificationofrimonabant(SR141716A)inmonkeyplasmausing

HPLCwithUVdetectionJChromatogrSci2010Jul;48(6):491-495.

28. Stewart JL,McMahon LR. Rimonabant-induced Δ9-tetrahydrocannabinolwithdrawal in rhesusmonkeys:discriminativestimuluseffectsandotherwithdrawalsignsJPharmacolExpTher2010Jul;334(1):347-356.

29. Giuffrida A, McMahon L. In vivo pharmacology of endocannabinoids and their metabolic inhibitors:

therapeuticimplicationsinParkinson‘sdiseaseandabuseliabilityProstaglandinsOtherLipidMediat2010Apr;91(3-4):90-103.

Invitedreview:Thisreviewexaminesnoveltargetswithintheendogenouscannabinoidsystemandsummarizespre-clinicalstudiesonthetherapeuticutilityofendogenouscannabinoidsandtheirmetabolicinhibitorsfortreatingmovementandsubstanceusedisorders.


10

30. Beardsley PM, Thomas BF, McMahon LR. Cannabinoid CB1 receptor antagonists as potentialpharmacotherapiesfordrugabusedisordersIntRevPsychiatry2009Apr;21(2):134-142.

Invitedreview:Thisreviewexaminespre-clinicalandclinicalstudiesonthetherapeuticutilityofcannabinoidantagonistsfortreatmentofabuseanddependencetoethanol,nicotine,opioids,andcocaine.

31. McMahonLR, Li J, Carroll FI, FranceCP. Someeffectsofdopamine transporterand receptor ligandson

discriminative stimulus, physiologic, and directly observable indices of opioid withdrawal in rhesusmonkeysPsychopharmacology(Berl)2009Apr;203(2):411-420.

32. McMahonLR.Apparentaffinityestimatesofrimonabant incombinationwithanandamideandchemical

analogs of anandamide in rhesusmonkeys discriminating Δ9-tetrahydrocannabinol Psychopharmacology(Berl)2009;203(2):219-228.

33. Gerak LR,McMahon LR, France CP. Acute cross tolerance to midazolam and not pentobarbital and

pregnanolone, after a single dose of chlordiazepoxide in monkeys discriminating midazolam BehavPharmacol2008Dec;19(8):796-804.

34. Li JX,McMahon LR, France CP, Li J. Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in

morphine-dependent and in nondependent rhesus monkeys. Psychopharmacology (Berl) 2008Jan;195(4):479-486.

35. Li J,McMahon LR, Gerak LR, Becker GL, France CP. Interactions between Δ9-tetrahydrocannabinol and

[mu] opioid receptor agonists in rhesus monkeys: discrimination and antinociception.Psychopharmacology(Berl)2008;199:199-208.

36. McMahonLR,GinsburgBC,LambRJ.Cannabinoidagonistsdifferentiallysubstituteforthediscriminative

stimulus effects of Delta(9)-tetrahydrocannabinol in C57BL/6J mice. Psychopharmacology (Berl). 2008Jul;198(4):487-95.

37. McMahonLR,KoekW.Differences intherelativepotencyofSR141716AandAM251asantagonistsof

variousinvivoeffectsofcannabinoidagonistsinC57BL/6JmiceEurJPharmacol2007Aug;569(1-2):70-76.

38. McMahon LR, Javors MA, France CP. Changes in relative potency among positive GABA(A) receptormodulators upon discontinuation of chronic benzodiazepine treatment in rhesus monkeysPsychopharmacology(Berl)2007;192:135-145.

39. McMahonLR.Discriminativestimuluseffectsof thecannabinoidCB(1)antagonistSR141716A in rhesus

monkeyspretreatedwithΔ9-tetrahydrocannabinol.Psychopharmacology(Berl)2006Oct;188(3):306-314.

40. McMahon LR, Gerak LR, France CP. Efficacy and the discriminative stimulus effects of negative GABAAmodulators, or inverse agonists, in diazepam-treated rhesus monkeys. J Pharmacol Exp Ther 2006Aug;318(2):907-913.


11

41. McMahon LR. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid

antagonists in rhesus monkeys discriminating Δ9-tetrahydrocannabinol. J Pharmacol Exp Ther 2006Aug;319(3):1211-1218.

42. France CP,Weltman RH, KoekW, Cruz CM,McMahon LR. Acute and Chronic Effects of Ramelteon in

RhesusMonkeys (Macacamulatta): Dependence Liability Studies. Behav Neurosci 2006 Jun;120(3):535-541.

43. McMahon LR, France CP. Differential behavioral effects of low efficacy positiveGABA(A)modulators in

combination with benzodiazepines and a neuroactive steroid in rhesus monkeys. Br J Pharmacol 2006Feb;147(3):260-268.

44. McMahonLR, FranceCP.NegativeGABA(A)modulatorsattenuate thediscriminative stimuluseffectsof

benzodiazepinesandtheneuroactivesteroidpregnanoloneinrhesusmonkeys.Psychopharmacology(Berl)2005Oct;181(4):697-705.

45. SzucsRP,FrankelPS,McMahonLR,CunninghamKA.Relationshipofcocaine-inducedc-Fosexpressionto

behaviorsandtheroleofserotonin5-HT2Areceptorsincocaine-inducedc-Fosexpression.BehavNeurosci2005Oct;119(5):1173-1183.

46. McMahonLR,AminMR,FranceCP.SR141716AdifferentiallyattenuatesthebehavioraleffectsofΔ9-THC

inrhesusmonkeys.BehavPharmacol2005Sep;16(5-6):363-372.

47. GaliciR,McMahonLR,FranceCP.Cross-toleranceandmuagonistefficacyinpigeonstreatedwithLAAMorbuprenorphine.PharmacolBiochemBehav2005Jul;81(3):626-634.

48. McMahon LR, France CP. Combined discriminative stimulus effects of midazolam with other positive

GABAAmodulators and GABAA receptor agonists in rhesus monkeys. Psychopharmacology (Berl) 2005Apr;178(4):400-409.

49. Sell SL,McMahon LR, KoekW, FranceCP.Monoaminergic drugs anddirectly observable signsof LAAM

withdrawalinrhesusmonkeys.BehavPharmacol2005Feb;16(1):53-58.

50. Benjamin LT Jr, Henry KD,McMahon LR. Inez Beverly Prosser and the education of African-Americans.JournaloftheHistoryoftheBehavioralSciences2005;41:43-62.

51. McMahon LR, Sell SL, France CP. Cocaine and other indirect-acting monoamine agonists differentially

attenuateanaltrexonediscriminativestimulusinmorphine-treatedrhesusmonkeys.JPharmacolExpTher2004Jan;308(1):111-119.

52. McMahonLR,FranceCP.Discriminativestimuluseffectsofthecannabinoidantagonist,SR141716A,inΔ9-

tetrahydrocannabinol-treatedrhesusmonkeys.ExpClinPsychopharmacol2003Nov;11(4):286-293.


12

53. SellSL,McMahonLR,FranceCP.Relativeefficacyofbuprenorphine,nalbuphineandmorphineinopioid-treatedrhesusmonkeysdiscriminatingnaltrexone.JPharmacolExpTher2003Sep;306(3):1167-1173.

54. McMahon LR, Cunningham KA. Discriminative stimulus effects of (-)-ephedrine in rats: analysis with

catecholaminetransporterandreceptorligands.DrugAlcoholDepend2003Jun;70(3):255-264.

55. McMahon LR, Coop A, France CP, Winger G, Woolverton WL. Evaluation of the reinforcing anddiscriminative stimulus effects of 1,4-butanediol and gamma-butyrolactone in rhesus monkeys. Eur JPharmacol2003Apr;466(1-2):113-120.

56. Bubar MJ, McMahon LR, De Deurwaerdère P, Spampinato U, Cunningham KA. Selective serotonin

reuptake inhibitors enhance cocaine-induced locomotor activity and dopamine release in the nucleusaccumbens.Neuropharmacology2003Mar;44(3):342-353.

57. McMahon LR, France CP. Discriminative stimulus effects of positive GABAA modulators and other

anxiolytics,sedatives,andanticonvulsants inuntreatedanddiazepam-treatedmonkeys.JPharmacolExpTher2003Jan;304(1):109-120.

58. McMahonLR,JerussiTP,FranceCP.Stereoselectivediscriminativestimuluseffectsofzopicloneinrhesus

monkeys.Psychopharmacology(Berl)2003Jan;165(3):222-228.

59. McMahonLR,FranceCP.Acuteandchroniceffectsoftheneuroactivesteroidpregnanoloneonschedule-controlledrespondinginrhesusmonkeys.BehavPharmacol2002Nov;13(7):545-555.

60. McMahonLR,FranceCP.Dailytreatmentwithdiazepamdifferentiallymodifiessensitivitytotheeffectsof

gamma-aminobutyric acid(A) modulators on schedule-controlled responding in rhesus monkeys. JPharmacolExpTher2002Mar;300(3):1017-1025.

61. McMahon LR, Gerak LR, Carter L, Ma C, Cook JM, France CP. Discriminative stimulus effects of

benzodiazepine (BZ1) receptor-selective ligands in rhesus monkeys. J Pharmacol Exp Ther 2002Feb;300(2):505-512.

62. McMahon LR, France CP. The negative GABA(A) modulator methyl beta-carboline-3-carboxylate

attenuates the behavioral effects of the positive GABA(A) modulators triazolam and pregnanolone inrhesusmonkeys.Psychopharmacology(Berl)2001Nov;158(3):289-296.

63. McMahonLR,FilipM,CunninghamKA.Differentialregulationofthemesoaccumbenscircuitbyserotonin

5-hydroxytryptamine(5-HT)2Aand5-HT2Creceptors.JNeurosci2001Oct;21(19):7781-7787.

64. McMahon LR, Gerak LR, France CP. Potency of positive gamma-aminobutyric acid(A) modulators tosubstitute for a midazolam discriminative stimulus in untreated monkeys does not predict potency toattenuateaflumazenildiscriminativestimulus indiazepam-treatedmonkeys.JPharmacolExpTher2001Sep;298(3):1227-1235.


13

65. McMahon LR, Cunningham KA. Antagonism of 5-hydroxytryptamine(2a) receptors attenuates thebehavioraleffectsofcocaineinrats.JPharmacolExpTher2001Apr;297(1):357-363.

66. McMahonLR,CunninghamKA.Roleof5-HT(2a)and5-HT(2B/2C)receptorsinthebehavioralinteractions

between serotonin and catecholamine reuptake inhibitors. Neuropsychopharmacology 2001Mar;24(3):319-329.

67. McMahonLR,CunninghamKA.Antagonismof5-hydroxytryptamine(4)receptorsattenuateshyperactivity

inducedbycocaine:putativerolefor5-hydroxytryptamine(4)receptorsinthenucleusaccumbensshell.JPharmacolExpTher1999Oct;291(1):300-307.

68. McMahon LR, Jones SL, Gilliland TR, Hall WD, Wellman PJ. Effects of ephedrine enantiomers onconditionedtasteaversionandkaolinintakeinrats.PharmacolBiochemBehav1999May;63(1):119-124.

69. MillerDK,McMahonLR,GreenTA,NationJR,WellmanPJ.Repeatedadministrationofephedrineinduces

behavioralsensitizationinrats.Psychopharmacology(Berl)1998Nov;140(1):52-56.

70. Wellman PJ, Miller DK, Livermore CL, Green TA,McMahon LR, Nation JR. Effects of (-)-ephedrine onlocomotion, feeding, and nucleus accumbens dopamine in rats. Psychopharmacology (Berl) 1998Jan;135(2):133-140.

71. McMahonLR,WellmanPJ.PVN infusionofGLP-1-(7-36)amide suppresses feedingbutdoesnot induce

aversionoralterlocomotioninrats.AmJPhysiol1998Jan;274(1Pt):23-29.

72. MillerDK,McMahonLR,GreenTA,Nation JR,WellmanPJ.Chronicadministrationofephedrine inducesbehavioralsensitizationinratsPsychopharmacology(Berl)1998;140:52-56.

73. McMahonLR,WellmanPJ.Decreasedintakeofaliquiddietinnonfood-deprivedratsfollowingintra-PVN

injectionsofGLP-1(7-36)amide.PharmacolBiochemBehav1997Nov;58(3):673-677.

74. McMahonLR,WellmanPJ.Assessmentoftheroleofoxytocinreceptorsinphenylpropanolamine-inducedanorexiainrats.PharmacolBiochemBehav1997Aug;57(4):767-770.

75. WellmanPJ,McMahonLR,GreenT,ToleA.Effectsofthealpha1a-adrenoceptorantagonistRS17053on

phenylpropanolamine-inducedanorexiaratsPharmacolBiochemBehav1997;57:281-284.

76. McMahon LR, Wellman PJ. Effects of systemic phenylpropanolamine and fenfluramine on serotoninactivitywithinratparaventricularhypothalamus.PhysiolBehav1996Jan;59(1):63-69.

77. McMahonLR,MorienA,DaviesBT,WellmanPJ.Conditionedtasteaversioninratsinducedbythealpha1-

adrenoceptoragonistcirazoline.PharmacolBiochemBehav1994Jul;48(3):601-604.


14

78. Wellman PJ, Tow S, McMahon LR. Isobolographic assessment of the effects of combinations ofphenylpropanolamine and fenfluramine on food intake in rats Pharmacol Biochem Behav 1994;50:287-291.

79. McMahonLR,MorienA,DaviesBT,WellmanPJ.Conditionedtasteaversioninratsinducedbythealpha1-

adrenoceptoragonistcirazolinePharmacolBiochemBehav1994;48:601-604.

80. WellmanPJ,DaviesBT,MorienA,McMahonLR.Modulationof feedingbyhypothalamicparaventricularnucleusalpha1-andalpha2-adrenergicreceptorsLifeSciences1993;53:669-679.

81. Morien A,McMahon LR, Wellman PJ. Effects on food and water intake of the alpha1-adrenoceptor

agonistsamidephrineandSK&F-89748LifeSciences1993;53:169-174. BookChapters 1. GinsburgBC,GerakLR,McMahonLR,RoacheJD.NeurosteroidsinalcoholandsubstanceuseIn:Ritsner

MS, Weizman A. Neuroactive Steroids in Brain Function, Behavioral and Neuropsychiatric Disorders:NovelStrategiesforResearchandTreatment.NewYork,NY:Springer;2008.p.509-536.

Thisbookchapterdescribesaroleforneurosteroidsintheabuseanddependenceliabilityofethanolandsedative/hypnotics acting through the GABAA receptor, and examines the utility of targeting brainneurosteroidstotreatethanol,benzodiazepineorbarbituratedependenceandwithdrawal.

2. WellmanPJ,McMahonLR.BasicmeasuresoffoodintakeIn:CurrentProtocolsinNeuroscience,Editors:

JCrawley,CGerfen,RMcKay,MRogawski,DSibley&PSkolnick.NewYork:Wiley;1997.

This unit describes amethod formeasuring the consumption of a pellet diet during a 30-min testingsession conductedduring the lateportionof thedayandhow it canbeused togenerate reliableandstablebaselinemeasuresof feeding. Experimentalmanipulations thateitherenhance (e.g., injectingapeptideintothebrain)orsuppressfeeding(e.g.,systemicinjectionsofamphetamine)alsoaredescribed.

3. McMahon LR,Wellman PJ. Basicmeasures of feeding In: Society for the Study of Ingestive BehaviorProtocols,Editors:PJWellman&BGHoebel.1997.

4. GreenTA,McMahonLR,WellmanPJ.MicrodialysisproceduresiningestivebehaviorresearchIn:Society

fortheStudyofIngestiveBehaviorProtocols,Editors:PJWellman&BGHoebel.1997.Books/Monographs 1. CPFrance,LRMcMahon,WEFantegrossi,WLWoolverton,GWinger,JCWinterandJHWoods.Progress

Report from the Testing Program for Stimulant andDepressantDrugs (2007) Proceedings, College onProblemsofDrugDependenceWashington,DC:USGovernmentPrintingOffice;2008.


15

2. WLWoolverton,WE Fantegrossi, CP France, LRMcMahon, GWinger and JHWoods. Progress ReportfromtheTestingProgramforStimulantandDepressantDrugs(2005)Proceedings,CollegeonProblemsofDrugDependenceWashington,DC:USGovernmentPrintingOffice;2006.

3. CP France, LRMcMahon,WE Fantegrossi,WLWoolverton, JCWinter and JHWoods. Progress Report

fromtheTestingProgramforStimulantandDepressantDrugs(2004)Proceedings,CollegeonProblemsofDrugDependenceWashington,DC:USGovernmentPrintingOffice;2005.

4. WE Fantegrossi, JH Woods, G Winger, LR McMahon, CP France, WL Woolverton, JC Winter and KA

Cunningham. Progress Report from the Testing Program for Stimulant and Depressant Drugs (2003)Proceedings,CollegeonProblemsofDrugDependenceWashington,DC:USGovernmentPrintingOffice;2004.

5. McMahon LR, France CP, Winger G, WoolvertonWL. Progress Report from the Testing Program for

Stimulant and Depressant Drugs (2002) Proceedings, College on Problems of Drug DependenceWashington,DC:USGovernmentPrintingOffice;2003.

Research/InvitedPresentations09/2017 Themushroomcure:usingpsychedelicdrugstotreatobsessive-compulsiveandotherhard-to-treat

psychiatric disorders, Office of the Vice President for Research and Education at University ofFloridaHealth,UniversityofFlorida(InvitedPanelist)

06/2017 Drug abuse, pain, and a vision for research enhancement, Department of AnesthesiologyGrand

Rounds,KansasUniversityMedicalCenter(InvitedSpeaker)06/2017 Direct-andindirect-actingcannabinoidreceptordrugs:Abuseandtherapeuticpotential,Schoolof

Pharmacy,UniversityofFlorida(InvitedSpeaker)05/2017 Synthetic cannabinoid overdose: Symptoms and treatment, Operation AdEPT: Addiction,

education, and prevention trainingWebinar series sponsored by Department of Psychiatry, TheUniversityofTexasHealthSanAntonio(InvitedSpeaker)

10/2016 Advancing pharmacy science and practice: Community and evidenced based research, School of

Pharmacy,TheUniversityofTexasatElPaso(InvitedSpeaker)04/2016 Acute tolerance to the discriminative stimulus effects of nicotine in monkeys, Symposium at

Experimental Biology/American Society of Pharmacology and Experimental Therapeutics, SanDiego,CA(InvitedSpeaker,presentedbymyPhDstudentMeganMoerke)

04/2016 Cannabinoid agonist-like effects of endogenous cannabinoid metabolic inhibitors, Behavioral

PharmacologySocietyAnnualMeeting,SanDiego,CA(Speaker)


16

02/2016 Upinsmoke:Mechanismsofnovelcannabinoid-andnicotinic-basedtherapeutics,DepartmentofPharmacology,TheUniversityofTexasHealthSanAntonio,TX(InvitedSpeaker)

05/2015 Cannabis-like effects of endogenous cannabinoid metabolic inhibitors, Center for Biomedical

Neuroscience,13thAnnualRetreat,SanAntonio,TX(InvitedSpeaker)04/2011 Discriminative stimulus effects of nicotinic receptor agonists in mice, Behavioral Pharmacology

SocietyAnnualMeeting,Washington,DC(Speaker)03/2011 Turnitup/turnitdown:varyingthemagnitudeofCB1receptorstimulationinnon-humanprimates.

ConventionalandNon-conventional,EndocannabinoidTargetsforCNSDisorders,AmericanSocietyforNeurochemistry,St.Louis,MO(InvitedSpeaker)

Assymposiumco-chair, Ihelpedchoosethe listofspeakersandpromoted integrationamongthe

presentations.01/2011 Enzymes,efficacy,andanewmarijuana:SocloseyetsoFAAHaway,AddictionSeminarSeries,The

UniversityofTexasHealthSanAntonio,TX(InvitedSpeaker)04/2010 Cannabinoid dependence and withdrawal: discriminative stimulus effects and other behavioral

indices,CenteronSubstanceAbuseResearch,TempleUniversity,Philadelphia,PA(InvitedSpeaker)04/2010 Whenthesmokeclears,there'smoretoneuronalnicotinicacetylcholinereceptors,Symposiumat

Experimental Biology/American Society of Pharmacology and Experimental Therapeutics,ExperimentalBiology/AmericanSocietyofPharmacologyandExperimentalTherapeutics,Anaheim,CA(InvitedSpeaker)

Assymposiumchair,Ichosethelistofspeakersandpromotedintegrationamongthepresentations.

03/2010 Cannabinoid dependence and withdrawal: discriminative stimulus effects and other behavioral

indices,CenterforDrugDiscovery,NortheasternUniversity,Boston,MA(InvitedSpeaker)02/2010 Cannabinoid dependence and withdrawal: discriminative stimulus effects and other behavioral

indices, Department of Pharmacology and Toxicology, Virginia Commonwealth University,Richmond,VA(InvitedSpeaker)

09/2009 Cannabinoid dependence and withdrawal: Drug discrimination and other behavioral indices,

Department of Pharmacology andNeuroscience,University of TexasHealth Science Center, FortWorth,TX(InvitedSpeaker)

06/2009 Drug withdrawal, reinforcing effects, and vulnerability to relapse: new methods and insights,

CollegeonProblemsofDrugDependenceAnnualMeeting,Reno,NV(SymposiumChair)


17

04/2009 Direct-andindirect-actingcannabinoidagonists:HowFAAHcanthisgo?,BehavioralPharmacologySocietyAnnualMeeting,Washington,DC(Speaker)

08/2008 Behavioral pharmacology of the cannabinoids in rhesus monkeys, Southwest Foundation for

BiomedicalResearch,SanAntonio,TX(InvitedSpeaker)06/2007 Discriminative stimulus effects of Δ9-tetrahydrocannabinol (Δ9-THC) in rhesusmonkeys receiving

morphine,heroin,ornaltrexone,CollegeonProblemsofDrugDependence,QuébecCity,Québec(Speaker)

06/2007 Effects of methanandamide in combination with Δ9-tetrahydrocannabinol (Δ9-THC) in C57BL/6J

mice discriminating Δ9-THC, College on Problems of Drug Dependence, Québec City, Québec(Speaker)

04/2007 Discriminative stimulus effects of rimonabant in monkeys treated with Δ9-THC, Behavioral

PharmacologySocietyAnnualMeeting,Washington,DC(Speaker)11/2006 Evaluatingtheacuteandchroniceffectsofcannabinoidswithcompetitiveantagonists,Behavioral

PharmacologyResearchUnit,JohnsHopkinsUniversity,Boston,MA(InvitedSpeaker)08/2006 Pre-clinical assessment of cannabinoids: Mechanism of action and consequences of chronic

treatment, Addiction Seminar Series, The University of Texas Health San Antonio, TX (InvitedSpeaker)

11/2005 Behavioraleffectsofcannabinoids:Involvementofmorethanonereceptorsubtype?,Department

ofPharmacology,TheUniversityofTexasHealthSanAntonio,TX(InvitedSpeaker)04/2005 Cannabinoidantagonisminmonkeysandmice,BehavioralPharmacologySocietyAnnualMeeting,

SanDiego,CA(Speaker)06/2004 Effects of cannabinoid agonists and antagonists in Δ9-tetrahydrocannabinol treated monkeys

discriminatingSR141716A,CollegeonProblemsofDrugDependence,SanJuan,PR(Speaker)04/2004 Drugdiscrimination:tolerancetobenzodiazepineswithoutcross-tolerancetoneuroactivesteroids

orbarbiturates,BehavioralPharmacologySocietyAnnualMeeting,Washington,DC(Speaker)06/2003 Effects of indirectmonoamine agonists inmorphine-treatedmonkeys discriminating naltrexone,

CollegeonProblemsofDrugDependence,BalHarbour,FL(Speaker)04/2003 To enhance or not to enhance: GABAA agonists and positive modulators in combination with

midazolam in rhesusmonkeys, Behavioral Pharmacology Society AnnualMeeting, SanDiego, CA(Speaker)


18

02/2003 Ethanol enhances the acute effects of benzodiazepines but does not attenuate benzodiazepinewithdrawalinrhesusmonkeys,TexasResearchSocietyonAlcoholism,SanAntonio,TX(Speaker)

06/2002 Discriminative stimulus effects of the cannabinoid antagonist SR141716A in Δ9-

tetrahydrocannabinoltreatedrhesusmonkeys,CollegeonProblemsofDrugDependence,QuébecCity,Québec(Speaker)

11/2001 Behavioral effects of GABAA modulators in nondependent and diazepam dependent rhesus

monkeys,Department of Pharmacology, TheUniversity of TexasHealth SanAntonio, TX (InvitedSpeaker)

06/2001 Positive GABAA modulators differentially attenuate the discriminative stimulus effects of the

neutralGABAAmodulator flumazenil indiazepamtreatedmonkeys,CollegeonProblemsofDrugDependence,Scottsdale,AZ(Speaker)

04/2001 Discriminative stimulus effects of GABAA/Benzodiazepine (BZ) modulators in rhesus monkeys:

studieswiththeBZ1antagonistbeta-CCt.SymposiumatExperimentalBiology/AmericanSocietyofPharmacologyandExperimentalTherapeutics,Orlando,FL(InvitedSpeaker)

MeetingAbstracts(since2000)

1. DeMouraFB,McMahonLR.ExaminingthecapacityofnAChRantagoniststoblocktheeffectsofnicotineinnicotine-tolerantC57BL/6Jmice.2017(CollegeonProblemsofDrugDependence).

2. DeMouraFB,McMahonLR.ExaminingthecapacityofnAChRantagoniststoblocktheeffectsofnicotineinnicotine-tolerantC57BL/6Jmice.2017p.986.13(FASEBJ;vol.31).

3. MoerkeMJ,McMahonLR.Increasednicotineexposuredecreasessensitivitytothenicotine-likeeffectsofAChEinhibitorsinmonkeysdiscriminatingnicotine.2016(CollegeonProblemsofDrugDependence).

4. Cocke ML,McMahon LR. Daily Synthetic Cannabinoid Agonist (JWH-018) Treatment: Tolerance to Δ9-Tetrahydrocannabinol-LikeDiscriminativeStimulusEffectsinRhesusMonkeys.2016p.703.4(FASEBJ;vol.30).

5. De Moura FB,McMahon LR. Differential Antagonism and Nicotine-Induced Tolerance/Cross-ToleranceAmongnAChRAgonistsinMice.2016p.1187.5(FASEBJ;vol.30).

6. MoerkeMJ,deMouraFM,KoekW,McMahonLR.EffectsofnicotineincombinationwithcompoundsthathaveprofilesinvitroconsistentwithpositiveallostericmodulationofnAChRs.2016(AmericanAssociationfortheAdvancementofScience).

7. MoerkeMJ,McMahonLR.DifferentialeffectsofpositivenAChRmodulatorsandAChEinhibitorsinrhesusmonkeysdiscriminatingnicotine.2015(SocietyforNeuroscience).


19

8. Cocke M, Moerke M, O'Connor J, McMahon LR. Hypothermic Effects of Δ9-THC and Nicotine in

Kynurenine-3-Monooxygenase(KMO)KnockoutMice.2015p.LB491M(FASEBJ;vol.29).9. Moura F,McMahon LR. The Discriminative Stimulus Effects of Nicotine, Epibatidine, and Varenicline in

Mice: Involvementofβ2ContainingNicotinicAcetylcholineReceptorSubtypes.2015p.1019.3(FASEBJ;vol.29).

10. MoerkeM,McMahonLR.CharacterizationofaNicotineDiscriminativeStimulusinRhesusMonkeys.2015

p.1019.5(FASEBJ;vol.29).11. Moura F,McMahon LR. Differential generalization among nicotinic acetylcholine receptor agonists in

nicotine,varenicline,andepibatidinedrugdiscriminationsinmice.2014p.661.11(FASEBJ;vol.28).

12. McMahonLR,CunninghamCS.Chronicnicotinetreatmentdifferentiallyaltersthediscriminativestimuluseffectsofnicotineandvareniclineinrhesusmonkeys.2013p.S540.(Neuropsychopharmacology;vol.38).

13. MouraFB,CunninghamCS,CarrollFI,OndachiP,McMahonLR.Discriminativestimuluseffectsofanovel

epibatidineanalogRTI-102inmice.2013(CollegeonProblemsofDrugDependence).14. RodriguezJS,McMahonLR.Hypothermiainmiceandgettinghigh:EvidencethatWIN55212-2andJWH-

018 have higher efficacy than Δ9-tetrahydrocannabinol (Δ9-THC). 2013 (International CannabinoidResearchSociety).

15. Cunningham CS,McMahon LR. Loss of sensitivity to varenicline in monkeys receiving chronic nicotine

treatment.2013p.1098.5(FASEBJ;vol.27).16. RodriguezJS,McMahonLR.DiscriminativestimuluseffectsofthesyntheticcannabinoidJWH-018inrhesus

monkeys.2013p.1097.6(FASEBJ;vol.27).17. HrubaL,NiphakisMJ,CravattBF,LichtmanAH,McMahonLR.InhibitionofbothFAAHandMAGL,butnot

eitherseparately,producesΔ9-THClikediscriminativestimuluseffects.2013p.1097.7(FASEBJ;vol.27).18. HrubaL,McMahon,LR. HU-210,CP47,497andΔ9-tetrahydrocannabinol:discriminativestimuluseffects

inrhesusmonkeys.2012(SocietyforNeuroscience).19. McMahon LR, Hruba L, Kinsey SG, O-Neal ST, Cravatt BF, Lichtman AH. Combined effects of a

monoacylglycerol lipase and fatty acid amide hydrolase inhibitor in mice discriminating Δ9-tetrahydrocannabinol.2012(InternationalCannabinoidResearchSociety).

20. CunninghamCS,McMahonLR.Enhancementandperceptualmaskingofanicotinediscriminativestimulus

inrhesusmonkeys.2012p.1040.11(FASEBJ;vol.26).


20

21. Hruba L, Ginsburg BC, and McMahon LR. Tolerance and cross-tolerance produced by Δ9-tetrahydrocannabinoltreatmentinrhesusmonkeys.2012p.660.6(FASEBJ;vol.26).

22. RodriguezJ,CunninghamC,CarrollFI,McMahonLR.Antagonismofthehypothermiceffectsofnicotinic

receptorligandsinmice.2012p.1048.5(FASEBJ;vol.26).23. CunninghamCS,McMahonLR.Discriminative stimuluseffectsofmecamylamine innicotine-treatedand

untreatedrhesusmonkeys.2012(CollegeonProblemsofDrugDependence).24. Rodriguez JS, Cunningham CS,McMahon LR. Discriminative stimulus effects of varenicline, a nicotinic

acetylcholinereceptor(nAchR)agonist,inmice.2012(CollegeonProblemsofDrugDependence).25. Cunningham CS,McMahon LR. Nicotinic receptors and the discriminative stimulus effects of nicotinic

receptoragonistsinrhesusmonkeys.2011(CollegeonProblemsofDrugDependence).26. McMahon LR, Schulze DR, Ginsburg BC. Effects of the cannabinoid JWH-018, a primary component of

K2/Spice,inrhesusmonkeys.2011(CollegeonProblemsofDrugDependence).27. Cunningham CS,McMahon LR. Effects of nicotine, varenicline, and cytisine in separate groups ofmice

discriminatingoneofthreedosesofnicotine.2011p.795.16.(FASEBJ;vol.25).

28. CunninghamCS,McMahonLR.Differentialantagonismof thebehavioraleffectsofnicotine,varenicline,andcytisineinmice.2010(CollegeonProblemsofDrugDependence).

29. Stewart JL,McMahonLR.DopamineD2-like receptorsmediate thediscriminativestimuluseffectsofΔ9-

tetrahydrocannabinol(Δ9-THC)inrhesusmonkeys.2010p.581.8(FASEBJ;vol.24).

30. CunninghamCS,McMahonLR.Nicotineandvareniclinesharediscriminativestimuluspropertiesandactthroughmecamylamine-sensitivereceptorsinrhesusmonkeys.2010p.580.4(FASEBJ;vol.24).

31. McMahonLR,KoekW.Bupropionexertscannabinoidantagonistactivityinrhesusmonkeys.2010p.S291

(Neuropsychopharmacology;vol.35).

32. Stewart JL, McMahon LR. Dopamine receptor agonists modify the discriminative stimulus effects ofrimonabantinΔ9-THCtreatedrhesusmonkeys.2010(CollegeonProblemsofDrugDependence).

33. McMahon LR, Stewart JL. Some effects of rimonabant in Δ9-tetrahydrocannabinol treated monkeys:

behaviouralandpharmacologicanalyses.2009p.P43(BehaviouralPharmacology;vol.20).

34. McMahon LR. Some behavioral effects of the fatty acid amide hydrolase inhibitor URB 597 in rhesusmonkeys.2009p.744.3(FASEBJ;vol.23).

35. McMahon LR. Relationship between cannabinoid agonist efficacy, tolerance, and cross-tolerance in Δ9-

tetrahydrocannabinol-treatedmonkeys.2008(CollegeonProblemsofDrugDependence).


21

36. McMahonLR.DifferentialdiscriminativestimulusandthermiceffectsofcannabinoidagonistsinC57BL/6L

mice.2007p.S81(BehavioralPharmacology;vol.18).

37. McMahon LR. Effects of methanandamide in combination with Δ9-tetrahydrocannabinol (Δ9-THC) inC57BL/6JmicediscriminatingDelta9-THC.2007(CollegeonProblemsofDrugDependence).

38. Carlisle J,McMahon LR. Discriminative stimulus effects of Δ9-tetrahydrocannabinol (Δ9-THC) in rhesus

monkeysreceivingmorphine,heroin,ornaltrexone.2007(CollegeonProblemsofDrugDependence).

39. McMahon LR. The effects of structural analogs of anandamide in rhesus monkeys discriminating Δ9-tetrahydrocannabinol(Delta9-THC).2007p.562.9(FASEBJ;vol.21).

40. Javors MA,McMahon LR. Quantification of rimonabant (SR 141716A) in plasma using HPLC with UV

detection.2007p.566.4(FASEBJ;vol.21).

41. Gerak LR, McMahon LR, France CP. Decreased sensitivity to midazolam and not pentobarbital orpregnanolonefollowingacutechlordiazepoxideadministrationinmonkeysdiscriminatingmidazolam.2006p.A235(FASEBJ;vol.20).

42. McMahon LR. Apparent pA2 analysis of cannabinoid antagonists in monkeys discriminating Δ9-

tetrahydrocannabinol(delta9-THC).2006p.A682(FASEBJ;vol.20).

43. GinsburgBC,McMahonLR.DiscriminativestimuluseffectsofΔ9-THCinC57BL/6Jmice.2006(CollegeonProblemsofDrugDependence).

44. AminMR,McMahonLR.DiscriminativestimuluseffectsofSR141716Ainrhesusmonkeystreatedwith2

mg/kg/dayofΔ9-THC.2006(CollegeonProblemsofDrugDependence).

45. Gerak LR, McMahon LR, France CP. Selective attenuation of the discriminative stimulus effects ofbenzodiazepines, and not other positive GABAAmodulators, by pentylenetetrazole in rhesusmonkeys.2006(CollegeonProblemsofDrugDependence).

46. McMahon LR, France CP. Discriminative stimulus effects of flumazenil in benzodiazepine-dependent

monkeys: Pharmacologic evaluation upon temporary discontinuation of treatment. 2006 (College onProblemsofDrugDependence).

47. France CP, Weltman R, Cruz C,McMahon LR. Ramelteon does not have benzodiazepine agonist-like

discriminativestimuluseffectsinnormalordiazepam-dependentrhesusmonkeys.2005.p.A5(Sleep;vol.28).

48. McMahon LR, AminMR, KoekW. SR 141716A and some behavioral effects of cannabinoid agonists in

mice:non-CB1receptors?2005p.S76(BehavioralPharmacology;vol.16).


22

49. AminMR, France CP,McMahon LR. Differential antagonism of a cannabinoid agonist by SR 14716A inrhesus monkeys. 2005 (American Society for Pharmacology and Experimental Therapeutics atExperimentalBiology).

50. McMahon LR, France CP. Discriminative stimulus effects of inverse agonists/antagonists at increasing

levelsofopioiddependence.2005(AmericanSocietyforPharmacologyandExperimentalTherapeuticsatExperimentalBiology).

51. McMahonLR,FranceCP.Benzodiazepineagonist-andantagonist-likediscriminativestimuluseffectsofL-

838,417 inrhesusmonkeys.2004(AmericanSocietyforPharmacologyandExperimentalTherapeuticsatExperimentalBiology).

52. McMahon LR, Sell SL, France CP. Discriminative stimulus effects of 6 alpha- and 6 beta-naltrexol in

morphine-andLAAM-dependentrhesusmonkeys.2003p.S52(BehaviouralPharmacology;vol.14).53. McMahon LR, Stone KK, JavorsMA, France CP. Behavioral and neuroendocrine correlates of diazepam

withdrawalinmonkeys.2002(AmericanCollegeofNeuropsychopharmacology).

54. FranceCP,McMahonLR.DiscriminativestimuluseffectsofthecannabinoidantagonistSR141716AinΔ9-THCtreatedrhesusmonkeys.2002(CollegeonProblemsofDrugDependence).

55. McMahonLR,France,CP.Discriminativestimuluseffectsof sedatives,anxiolyticsandanticonvulsants in

diazepam dependent and non-dependent rhesus monkeys. 2002 (College on Problems of DrugDependence).

56. McMahon LR, France CP. Neuroactive steroids: synergism with benzodiazepines and prevention of

benzodiazepine withdrawal in rhesus monkeys. 2002 (American Society for Pharmacology andExperimentalTherapeuticsatExperimentalBiology).

57. McMahon LR, France CP. Enhanced sensitivity to the rate-decreasing effects of the CB1 receptor

antagonistSR141716AinrhesusmonkeyschronicallytreatedwithΔ9-tetrahydrocannabinol(Δ9-THC).2001(EuropeanBehaviouralPharmacologySocietyandEuropeanBrainandBehaviourSociety).

58. CunninghamKA,FilipM,McMahonLR,SzucsRP,FrankelPS.Controlofthemesoaccumbenspathwayby5-

HT2A and 5-HT2C receptors: lessons frommicroinjection and c-Fosmapping analyses. 2001 (EuropeanBehaviouralPharmacologySocietyandEuropeanBrainandBehaviourSociety).

59. McMahonLR,GerakLR,FranceCP.PositiveGABAAmodulatorsdifferentiallyattenuatethediscriminative

stimuluseffectsof theneutralGABAAmodulator flumazenil indiazepam treated rhesusmonkeys.2001(CollegeonProblemsofDrugDependence).

60. McMahonLR,CarterL,GerakLR,FranceCP.DiscriminativestimuluseffectsofGABAA/Benzodiazepine(BZ)

modulators in rhesus monkeys: studies with the BZ1 antagonist beta-CCt. 2001 (American Society forPharmacologyandExperimentalTherapeuticsatExperimentalBiology).


23

61. France CP, Gerak LR, McMahon LR. Differential effects of positive GABAA modulators in diazepam-

dependentmonkeys.2000(AmericanCollegeofNeuropsychopharmacology).

62. McMahon LR, BubarMJ, Cunningham KA. Potentiation of cocaine-induced hyperactivity by infusion ofselective serotonin reuptake inhibitors into the rat nucleus accumbens shell. 2000 (Society forNeuroscience).

63. Szucs RP,McMahon LR, Frankel PS, Cunningham KA. Effects of the 5-HT2A receptor antagonist MDL

100,907oncocaine-inducedc-Fosexpression.2000(SocietyforNeuroscience).

64. McMahon LR, Szucs RP, Cunningham KA. Influence of 5-HT2A receptors on molecular and behavioralresponses to cocaine: role of medial prefrontal cortex and dorsomedial striatum. 2000 (College onProblemsofDrugDependence).

65. UllrichT,FantegrossiW,McMahonLR,CunninghamKA,WoodsJH,RiceKC.Newchemicalandbiologicalstudies onMDL 100907, a highly selective serotonin 50HT2A antagonist. 2000 (College on Problems ofDrugDependence).


24

TEACHING

TheUniversityofTexasHealthSanAntonioTeaching

2015-Present PHAS6014Pharmacology,PhysicianAssistantStudents Lecturer:45students

Description: reviews actions and therapeutic uses of drugs, principles of pharmacology,pharmacokinetics, autonomic and cardiovascular pharmacology, neuropharmacology, endocrinepharmacology, GI and respiratory pharmacology, chemotherapy and toxicology, and basics inprescriptionwriting.

2013-Present CIRC6007Mind,BrainandBehavior,MedicalStudents Lecturer:200students

Description: theneurology-andpsychiatric-basednervoussystemmodule takenby2nd-yearmedicalstudents.Iparticipateinmultipleclassesinamultidisciplinaryteamtoprovideinstructiononthebasicscience,diagnosisandcasemanagement,andtherapeuticsforanxietyandsubstanceabusedisorders.

2012-Present INTD5040FundamentalNeuroscience,MD/PhDStudents Lecturer:15students

Description:broadsurveyofthebasicsofmolecular,cellular,anddevelopmentalneuroscience.Iteacha class on the molecular and cellular mechanisms of GABAA neurotransmission and therapeuticconsequencesofGABAAreceptordrugs.

2008-Present PHAR5001Pharmacology,DentalStudents Lecturer:100students

Description: overview of the general principles of drug action for the treatment and alleviation ofsymptoms of medical and dental diseases including pharmacodynamics of major drug groups,toxicology, and contemporary prescriptionwriting.My contribution covers the basic anatomy of theCNSand thepharmacologyand therapeuticsofanti-anxietyandhypnoticdrugs,whichare themostcommonlyprescribedbydentists.

2009-Present PHAR5020BasicsofResearchDesign,MD/PhDStudents Director:15students

Description: 2-credithour course requiredof2nd-yearpharmacologyandneurosciencePhDstudentsdividedintotwosections:1)overviewofresearchdesignandstatisticsand2)communicatingscientificideasthroughgrantwriting.Thecoursehasaheavywritingcomponent.

2011-Present PHAR5013PrinciplesofPharmacology,MD/PhDStudents Lecturer:15students

Description:surveysprinciplesofdrugaction.Ihavetwolectures:onereviewsreceptormechanismsofdrugtoleranceandthesecondreviewspharmacokineticandpharmacodynamicdeterminantsofdrugdependenceandwithdrawal.

2008-2014 PHAR5091Therapeutics,MD/PhDStudents Director:10students


25

Description: overview of therapeutic considerations of major drug classes for treatment of anxiety,sleepdisorders,depression,schizophrenia,andsubstanceusedisorders.

2010,2013 CSBL6021AnimalModels,PhDStudents Lecturer:10students

Description: overview of animal models used for biomedical research with emphasis on primaryscientificliterature.Ireviewpre-clinicalassayssensitivetopsychotherapeutics.

2010 CAINEProgramLecturesinAddiction,Teachers Lecturer:10students

Description:CAINE (CriticalAppraisal to ImproveNeuroscienceEducation) isagrant-fundedprogramforscience-certifiedmiddleschoolteachers.Ireviewedbasicsofdrugabuse.

2010-Present PharmacologyTrackJournalClub,PhDStudents Director:20students

Description: required of pharmacology track students. Students choose a paper and present it tostudents and faculty. Improves critical thinking and develops presentation skills. I coordinate andprovidefeedbacktostudentsonstrengthsandareasinneedofimprovement.

2008-Present AddictionJournalClub,StudentsandFaculty

Description: biweekly journal club consistingof PhD students, postdoctoral traineesand facultywithmutual interests in pharmacology, behavior, and addiction. Faculty take turns selecting andcoordinating8-10articlespertopicsection.

UniversityofHoustonClearLakeTeaching1997-2000 CurrentPerspectivesinPsychologyI,Undergraduate Director:60students

Description:advancedpsychologycourse;extendedoverviewofseveralmajortopicdomainsincludingthepsychologyhistory,languagedevelopment,motivation,emotion,socialpsychology,andabnormalpsychology.

1998 CurrentPerspectivesinPsychologyII,Undergraduate Director:60students

Description:advancedpsychologycourse;extendedoverviewofseveralmajortopicdomainsincludingthebiologicalbasisofbehavior,sensationandperception,consciousness,learning,memory,cognition,intelligence,andappliedfieldsincontemporarypsychology.

1999 BiologicalBasisofBehavior,Masters Director:10students1999 BrainandBehavior,Undergraduate Director:30students


26

Description: reviewed the CNS (neurons, synapses, action potentials, neurotransmitters, andneuroanatomy)anditsmodulationofbehavior,includingsensoryperception,motorcontrol,sleepandawareness,drives,emotions, learning,and language,aswellasdisease includingdepression,bipolardisorder,schizophrenia,Parkinson’s,Alzheimer’s,andaphasias.

1998 LearningandBehavior,Undergraduate Director:30students

Description:basicoverviewofclassicalandoperantconditioning,includingahands-onprojectallowingstudents to shape simple behavior, establish a basic schedule of reinforcement, and interpretcumulativerecords.

1997-2000 BehaviorallyActiveDrugs,Masters Director:10students1998 DrugsandBehavior,Undergraduate Director:30students

Description: overviewofCNS-actingdrugeffectsonmental stateandbehavior. Several abuseddrugclasseswereexaminedaswellaspsychotherapeuticsforanxiety,depression,andschizophrenia.

TexasA&MUniversityTeaching1996 IntroductiontoPsychology,Undergraduate Co-Director:300students

Description:Introductorycoursedealingwithelementaryprinciplesofhumanbehavior.AsaseniorPhDstudent in theDepartment of Psychology at TexasA&MUniversity Iwas amonga select group in aseries of courses on cutting-edge pedagogy in psychology education under the guidance of Ludy T.Benjamin Jr. PhD, Presidential Professor of Teaching Excellence, Professor of Psychology andEducationalPsychology.

DissertationCommitteeMembership2012 VeronicaHargrove

Title: Postmortem redistribution of morphine and citalopram: The role of vasculartransport,tissuereservoirsandvolumeofdistribution

2015 BlaineJacobs

Title:Deltaopioid receptor-kappaopioid receptor (DOR-KOR)heteromers inperipheralpain-sensingneurons:noveltargetsforimprovedpainpharmacotherapy?

DissertationProposalExamination,CommitteeonGraduateStudies

2011 JacobJunco

Title: Effects of phytonutrients ursolic acid and resveratrol in skin cancer-relevantsystems

2011 AlexandraSoto-Pina


27

Title: Does the peripheral sympathetic nervous system contribute to hypertensioninducedbychronicdexamethasonetreatment?

2011 MargaretWey Title:Deficientaldehydedetoxificationinthenigrostriatalpathway:apotentialanimal modelforParkinson’sdisease2010 HaTruong Title:Behavioralandneurochemicaleffectsofvagalnervestimulationintherat 2009 MatthewRowan Title:Estrogenregulationofbradykininsignaling 2009 MichelleBaladi Title:Impactoffeedingconditiononsensitivityofratstodopaminedrugs 2009 JacobGarza

Title:EffectsofleptinonadulthippocampalneurogenesisQualifyingExamCommittees 2010 XiangBai2011 VeronicaHargrove2014 KelseySmith2017 ArianaCruz

PostdoctoralTraineesSupervised 2011-2013 JesseRodriguez,PhD

CurrentPosition:ResearchAssistantProfessor,DepartmentofNeurosurgery,UTHealthSanAntonio

2011-2013 LenkaHruba,PhD

Current Position: Humboldt Postdoctoral Fellow, Werner Reichardt Centre forIntegrativeNeuroscience

2009-2010 JenniferStewart,PhD CurrentPosition:AssociateChairofSciences,GalenCollegeofNursingPhDStudentsSupervised 2012-2017 FernandoMoura,PhD

CurrentPosition:PostdoctoralFellow,PreclinicalPharmacologyProgram,HarvardUniversity


28

2011-2016 MeganMoerke,PhD

Current Position: Postdoctoral Fellow, Department of Pharmacology and Toxicology,VirginiaCommonwealthUniversity

2008-2013 ColinCunningham,PhDCurrentPosition:PostdoctoralFellow,BehavioralPharmacologyResearchUnit,JohnsHopkinsUniversity

Master’sStudentSupervised 2005 MaryseAmin,UniversityofTexasatSanAntonio

Title:Behavioraleffectsofcannabinoidsinmonkeys GraduateStudentResearchRotations 2014 MorganCocke2012 FernandoMoura2011 MeganMoerke2009 JamesGroh

2008 ColinCunningham

2008 HarinderSinghUndergraduateHonorsThesisSupervised

2012 MatthewForster(UniversityofTexasSanAntonio)

Project entitled “Tolerance to nicotine and cross-tolerance to varenicline in mice:hypothermiceffects”

2011 SamanthaKetcham(TexasA&MUniversityHonorsProgram)

ASPET Summer Undergraduate Research Program project entitled “Discriminativestimuluseffectsofvareniclineandnicotineinmice:interactionswith5-HT3receptors”

2011 BrittanyWeems(UniversityofNotreDameHonorsProgram)

ASPET Summer Undergraduate Research Program project thesis “Pharmacologyunderlyingthebehavioraleffectsofnicotinicagonistsinmice”

2010 ChristinaGeorge(OurLadyoftheLakeUniversityHonorsProgram)


29

McNair Scholars Research Program project entitled “Chronic nicotine treatment:toleranceandcross-toleranceamongnicotinicagonistsinC57BL/6Jmice?”

2009 AmandaTristan(St.Mary’sUniversityHonorsProgram)

McNair Scholars Research Program project entitled “Chronic effects of nicotine inC57BL/6Jmice”

2008 LaurenHowe(UniversityofKentuckyHonorsProgram)

ASPET Summer Undergraduate Research Program project entitled “Effects of nicotineandvarenicline,aloneandincombinationwithmecamylamine,inC57BL/6Jmice”

2007 YaminSun(UniversityofTexasatAustinHonorsProgram)

ASPET Summer Undergraduate Research Program project entitled “Acute effects ofmecamylamineandnicotineonfixedratiorespondinginC57BL/6Jmice”

2006 KimberlyMeuth(TexasStateUniversityHonorsCollege)

ASPET Summer Undergraduate Research Program project entitled “Acute and chroniceffectsofΔ9-tetrahydrocannabinolonaggressioninC57BL/6Jmice”

2005 AlexRancier(Huston-TillotsonUniversityW.E.B.DuBoisHonorsProgram)

ASPETSummerUndergraduateResearchProgramprojectentitled“InteractionsbetweenΔ9-tetrahydrocannabinol and CB1 antagonists on directly observable behavior inC57BL/6Jmice”

2003-2004 HilariShaePatyrak(UniversityofTexasSanAntonioHonorsCollege)Project entitled “Involvement of µ opioid receptors in thermal allodynia induced bycapsaicininrhesusmonkeys”

HighSchoolHonorsThesisSupervised2013-2014 JeffreyChilders(STEMAcademyatRobertE.LeeHighSchoolinSanAntonio,TX)

UT Health San Antonio Voelcker Academy Scholar project entitled “ToleranceobservationthroughhypothermiceffectsofnicotineandRTI-102inmice”

ResearchStaff(MinimumBachelor’sDegree)UnderMyDirection

LindyAgate,ResearchAssociateDaniaAquirre,SeniorResearchAssistantJohnBuswold,ResearchAssistantVictoriaCarleton,ResearchAssistant(ClinicalTrialsManagerGenevaFoundation)JenniferCarlisle,ResearchAssistantCoryCrowe,ResearchAssistantAdelaGarza,ResearchAssistantLeahHargrove,ResearchAssistant(lefttoenterPhDprogram)


30

WalterHolbein,ResearchAssistant(postdocMayoClinic,nowPhysiologistatNoninMedical,Inc.)JennaKranz,ResearchAssistantCrystalRock-Frederickson,ResearchAssistant(PhDstudentUTSanAntonio)DavidSchulze,ResearchAssociate(medicalstudentUniversityofNorthTexasHealthScienceCenter)AjitaShah,ResearchAssistant(MDemergencymedicineandmodelAustin,TX)NoemiSolis,ResearchAssistantJuliaThreadgill,ResearchAssistant(SafetySpecialistUTHealthSanAntonio)AmandaTristan,ResearchAssistantJesseUsrey,ResearchAssistantAshleyVarnon,ResearchAssistant(MDinternalmedicineUTHealthSanAntonio)ArmiaZaki,ResearchAssistant(dentalstudentUTHealthSanAntonio)


31

SERVICE

NIHStudySectionReviews

2015-2017 SpecialEmphasisPanel:Alcohol,NeurotoxicityandDrugs2017-2021(Member) BiobehavioralRegulation,LearningandEthologyStudySection 2016 20062011-2017 NIHPre-/Post-DocFellowshipStudySection:BehavioralNeuroscience2011 ProgramProjectStudySection:NewMolecularEntities toTreatSubstanceUse

Disorders(NIDASpecialEmphasisPanel)2011 NewMolecularEntitiestoTreatSubstanceUseDisorders

(NIDASpecialEmphasisPanel)2006-2007 NIDAMedicationDevelopment(NIDA-L) 2006 TrainingandCareerDevelopment(NIDA-K)ScientificJournalReviewsInternationalJournalofNeuropsychopharmacologyFieldEditor

BehaviouralPharmacologyBrainResearchDrugandAlcoholDependenceExperimentalandClinicalPsychopharmacologyJournalofPharmacologyandExperimentalTherapeuticsPharmacologyBiochemistryandBehaviorPsychopharmacologyInternationalReviewofPsychiatryInstituteforLaboratoryAnimalResearch(ILAR)JournalNeuropharmacologyProstaglandinsOtherLipidMediatorNationalandInternationalCommittees2008-2011 ProgrammingCommittee,CollegeonProblemsofDrugDependence

The flagshipscientificorganizationof theNational InstituteonDrugAbuse.Programmingcommitteemembers are responsible for choosing 12-14 symposia from among approximately 60 symposium


32

applications.Thiscommitteealsojudgesapproximately1000researchabstractsandprogramsoralandposterpresentations.

2009-2011 ExecutiveCommittee,DivisionofBehavioralPharmacology

AmericanSocietyofPharmacologyandExperimentalTherapeutics

Responsibilities includedmeeting several times per year (via teleconference and during the annualExperimentalBiologymeeting) todiscuss scientificprogramming,budget, studentandpost-doctoralresearchcompetitions,outreachactivities,andotherbusiness relevant to thedivision. Inaddition, Iled fund-raisingandorganizingefforts forgraduatestudent/post-doceventheld inconjunctionwiththeannualExperimentalBiologymeeting.Thepurposeofthiseventwastobringtogetherjuniorandseniormembershipinarelaxedenvironmentwherevaluablecareerandprofessionaladvicecouldbeexchanged.

2002-2009 President,SocietyforNeuroscienceAlamoChapter

Led an elected board of scientists from various universities in San Antonio to promote neuroscienceresearch.Solicitedtravelawardapplicationsfromthemembership,coordinatedreview,andidentifiedtwooutstandingneurosciencegraduatestudentsandonepost-doctoralfellowtorepresenttheAlamoChapter.FundsweresuccessfullyobtainedfromtheSocietyforNeurosciencefortraveltobothnational(annualmeetingoftheSFN)andinternationalmeetings(IBRO).

2009-2016 ExecutiveOrganizingCommittee

Chair,TravelAwardsCommitteeBehavior,Biology,andChemistry:TranslationalResearchinAddictionConference

Two-day international conference held annually in San Antonio to promote translational researchamong chemists, biologists, and behavioral scientists in drug addiction. Coordinated and scheduledresearchpresentations(plenarysymposium,oralcommunications,andpostercommunications)andallmeeting-relatedactivities.Coordinatedreviewofstudentawardapplications,selectedtravelawardees,budgetedtravelawards,supervisedoralandposterpresentationjudging,selectedawardwinners,anddisseminatedwrittenfeedbacktojuniorpresentersaftertheconference.

2017 ExecutiveBoard,TexasResearchSocietyonAlcoholism

Organizationthatpromotesresearchtounderstand,prevent,andtreatalcoholismandothersubstanceuse disorders; to extend scientific knowledge of these disorders; and to promote interaction andcommunicationamongresearchscientistsinTexasandsurroundingstates.


33

TheUniversityOfTexasHealthSanAntonioCommitteesUniversity2014-Present CouncilofPrincipalInvestigators

Electedposition from theUTHealthSanAntonio research community. TheCPI’smission is toensurecontinued improvementof theresearchenvironment for faculty, studentsandstaffatUTHealthSanAntonio.TheCPI,actingasavoiceforthePIsitrepresents,workswithadministrationtooptimizetheefficiencyandeffectivenessoftheresearchandtrainingenvironment,withthegoalof increasingthenationalrecognitionofUTHealthSanAntonioasaninstitutioncompetitive inresearchandteaching.The CPI meets at least monthly to consider specific issues relevant to research and graduateenvironments. Recommendations are formulated, then discussedwith and implemented through theappropriateorganizationsoradministrativeoffices.

2007-2010 InstitutionalAnimalCareandUseCommittee

Faculty oversight committee appointed by the university President to ensure that all programsconcerning the care and use of laboratory animals are following Federal and university rules andregulations. The IACUC is responsible for: 1) Assuring that the use of animals in research, teachingand/or education is in accordance with institutional and Federal guidelines; 2) Assisting the facultywhoseresearchendeavors involveanimals;3)ReviewingtheprogramsforthecareandtreatmentofanimalsatleastsemiannuallytoassesscompliancewithinstitutionalandFederalstandards;4)Reviewallprotocolsadvocatingtheuseofanimalsinresearch,teachingoreducationasneeded,butatleastonasemiannualbasis.

2012 SearchCommittee,DirectorofOfficeofPostdoctoralAffairs Selected the inaugural Director of OPA, a milestone at the university for supporting postdoctoral

trainingandprofessionaldevelopment.SchoolofMedicine 2014-Present CurriculumCommittee

Establishes the requirements for the degree of Doctor of Medicine, evaluates the quality andorganization of the current curriculum, and develops and recommends to theDean of the School ofMedicine strategies for implementing changes in the content, scope, and sequence of courses,selectives, and electives. I am also a member of the Design and Integration subcommittee. Thissubcommitteecontinuallymonitorsthecurriculumdesignofallfouryearsofmedicalschooltoinclude,but not be restricted to, the following aspects ofmandatory and elective courses/rotations: Contacthours,pedagogy,content,assessment,etc.,andbringsrecommendationstothecurriculumcommitteewhen appropriate. Any changes to standing courses/clerkships/rotations are presented to this


34

subcommittee by the course director. These changesmay include contact hours, pedagogy, content,grading,objectives,etc.Anynewcourseproposalswillbepresentedtothissubcommittee.

2008-2009 AdmissionsCommittee

Conducted 30-min interviews and provided comprehensive written summaries of the interview forapproximately30medicalschoolapplicants.

2014-2015 InternalGrantReviewer

BridgeFundsandPilotProgramProjects

ServedwithotherUTHealthSanAntoniofacultyaspeerreviewersofapplicationsforbridgeandpilotprogramprojectscoordinatedthroughtheofficeoftheassociatedeanforresearch.

GraduateSchoolofBiomedicalSciences2011-2014 AdmissionsCommittee

Amulti-departmentalbodyresponsibleforevaluatingallapplicationsforadmissionforPhDprogramsinthegraduateschoolofbiomedicalsciences.Metasacommitteeweeklyoverthecourseofseveralmonths,intervieweddomesticandforeigncandidates,grantedadmission,andawardedscholarshipstothemostqualifiedcandidates.

DepartmentofPharmacology 2013-Present PromotionsandTenureCommittee

Reviews applications for promotion to associate professor with tenure or full professor and makesrecommendationsforapprovaltothedepartmentchair.

2009-2012 ASPETSummerUndergraduateResearchProgramAdmissionsCommittee

Responsibleforreviewingapplicationmaterialsandidentifyingthetopcandidatestoreceiveofferstoparticipateinthesummerundergraduateresearchprogram.

2009-2012 CommitteeonGraduateStudies

Monitors studentacademicprogress, coordinates selectionofdissertation supervisorand supervisingcommittees, coordinatesandparticipates in studentqualifyingexams,and resolves student issuesasneeded.


35

2007-2010 CurriculumCommittee

Steeringcommitteeofpharmacologycurriculuminthegraduateschoolofbiomedicalsciences.2006-2009 Chair,AdjunctandCrossAppointmentCommittee

Reviewed adjunct and cross appointment applications and coordinated meetings with committeememberstorecommendselectedcandidatestothepharmacologyChair.

Other 2007-2010 PharmacologyDepartmentSeminarSeriesCoordinator

Coordinateweeklyseminarsandintroducespeakers.

2006-1010 PharmacologyDepartmentGraduateStudentResearchForum

Posterjudge2004-2007 PharmacologyDepartmentGraduateStudentInterviews

InterviewedgraduatestudentapplicantstoourGraduatePrograminPharmacology2007-Present GraduateSchoolofBiomedicalSciencesStudentApplicantInterviews

Interviewed andmet with graduate student applicants to the IntegratedMultidisciplinary GraduateProgram

2009-2011 CenterforBiomedicalNeuroscienceResearchForum

Posterjudge

2002-2011 SocietyforNeuroscienceBrainBowlCompetitionJudge

Preparedquestions judgedcontestantsataquizbowlstylecompetitionamongundergraduateteamsfromTexasuniversitiesontheirknowledgeofvarioustopicsinneuroscience.

PromotionandTenureReviews2009VirginiaCommonwealthUniversity2012TheUniversityofTexasHealthSanAntonioMembershipinProfessionalAffiliations


36

AmericanAssociationofCollegesofPharmacyAmericanSocietyofPharmacologyandExperimentalTherapeuticsBehavioralPharmacologySocietyCollegeonProblemsofDrugDependenceSocietyforNeuroscienceHonorsandAwards

1999 FederationofAmericanSocietiesforExperimentalBiologyTravelAward

1999 CollegeonProblemsofDrugDependenceTravelAwardFellowship

1999 NationalInstituteonDrugAbuseDirector’sTravelAward

1998 TexasA&MUniversityDistinguishedGraduateStudentAward

1997 TexasA&MUniversityFacultyofNeuroscienceTravelAward


1996 TexasA&MUniversityDepartmentofPsychologyTravelAward



1995 SocietyfortheStudyofIngestiveBehaviorYoungInvestigatorAward



37

PROFESSIONALREFERENCES

JackBergman,PhDAssociateProfessorofPsychobiologyDepartmentofPsychiatry,McLeanHospitalHarvardUniversity617-855-2464jbergman@mclean.harvard.edu

KathrynA.Cunningham,PhDProfessorandViceChairofPharmacologySchoolofMedicineUniversityofTexasMedicalBranch409-772-9640kcunning@utmb.edu

CharlesP.France,PhDProfessorofPharmacologySchoolofMedicineUniversityofTexasHealthSanAntonio210-567-6969france@uthscsa.edu

AlanFrazer,PhDProfessorandChairofPharmacologySchoolofMedicineUniversityofTexasHealthSanAntonio210-567-4205frazer@uthscsa.edu

AndreaGiuffrida,PhDVicePresidentforResearchProfessorofPharmacologyUniversityofTexasHealthSanAntonio210-567-4219giuffrida@uthscsa.edu

DavidS.Weiss,PhDDeanGraduateSchoolofBiomedicalSciencesUniversityofTexasHealthSanAntonio210-567-3713weissd@uthscsa.edu

curriculum vitae lance richard mcmahon, phd …neuropharmacology 2016 dec;116:9-17. 4. cunningham...

Documents